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AbstrAct:
Introduction. Pathogenic variations in C19orf12 are responsible for two allelic diseases: mitochondrial membrane protein-as-
sociated neurodegeneration (MPAN); and spastic paraplegia type 43 (SPG43). MPAN is an orphan disease, which presents with 
spasticity, dystonia, peripheral nerve involvement, and dementia. The pattern of iron accumulation on brain MRI may be a clue 
for the diagnosis of MPAN. SPG43, on the other hand, is characterised by progressive lower limb spasticity without brain iron 
accumulation. We here present clinical and genetic findings of MPAN patients with potentially pathogenic C19orf12 variants.
Materials and methods. Patients from 13 different families having progressive motor symptoms with irritative pyramidal signs 
and brain iron accumulation were screened for C19orf12 gene variants.
results. C19orf12 screening identified seven variants associated with MPAN in eight patients from seven families. We associated 
two pathogenic variants (c.24G > C; p.(Lys8Asn) and c.194G > A; p.(Gly65Glu)) with the MPAN phenotype for the first time. We 
also provided a genetic diagnosis for a patient with an atypical MPAN presentation. The variant c.32C > T; p.(Thr11Met), common 
to Turkish adult-onset MPAN patients, was also detected in two unrelated late-onset MPAN patients.
conclusions. Genetic analysis along with thorough clinical analysis supported by radiological findings will aid the differential 
diagnosis of MPAN within the neurodegeneration with brain iron accumulation spectrum as well as other disorders including 
hereditary spastic paraplegia. Dystonia and parkinsonism may not be the leading clinical findings in MPAN patients, as these 
are absent in the atypical case. Finally, we emphasise that the existence of frameshifting variants may bias the age of onset 
toward childhood.
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Introduction
Neurodegeneration with brain iron accumulation (NBIA) 
comprises a group of rare inherited movement disorders ac-
companied by varying degrees of cognitive dysfunction. The 
combination of extrapyramidal motor system involvement and 
iron accumulation at the basal ganglia on brain magnetic res-
onance imaging (MRI) leads simply to a suspicion of an NBIA 
disorder. However, identifying the distinct NBIA subtype can 
be challenging due to clinical and genetic heterogeneity [1, 2]. 
477www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Nihan Hande Akçakaya et al., Clinical and genetic spectrum of an orphan disease MPAN
Mitochondrial membrane protein-associated neurodegener-
ation (MPAN) is the third most frequent subtype of NBIA 
(MIM:614298). MPAN, also known as NBIA4 and first defined 
in a Polish NBIA cohort, comprises 38% of total cases [1]. The 
C19orf12 protein shows mitochondrial localisation. Lewy 
bodies, tangles, spheroids, and tau pathology were present 
in histopathological examination of the brain in an autopsy 
case [1]. The major clinical features of MPAN are  spasticity, 
dystonia, peripheral nerve involvement, and dementia [1]. 
The prominent clinical features of MPAN may show a great 
variability among patients, such as manifesting severe periph-
eral motor axonal neuropathy or amyotrophic lateral sclerosis 
mimicking clinical progress [1–3].
The age of MPAN onset can vary from childhood to 
adulthood. The earliest onset of MPAN has been reported 
at the age of 3, and the oldest at the age of 36 [3, 4]. Initial 
symptoms involve movement abnormalities, behavioural 
disturbances, cognitive impairment, optic atrophy, motor 
axonal neuropathy, and bladder incontinence [5]. Gait 
problems and spasticity, predominantly in the lower limbs, 
are also early symptoms of MPAN [1]. In early onset MPAN 
cases, dystonia and spasticity comprise the most common 
motor symptoms. Parkinsonism is mostly observed in cases 
with a later onset. Emotional lability, anxiety, compulsions, 
depression, impulsiveness and psychosis are the non-motor 
symptoms [5]. The rate of progression of MPAN is not clearly 
defined, but adulthood onset cases can show an aggressive 
progression leading to death [4–6].
The radiological spectrum of MPAN is also heteroge-
neous, without a distinct MRI sign. Nevertheless, the main 
MRI finding is iron accumulation at globus pallidus (GP) 
equally with substantia nigra (SN) [1, 5]. However, iron 
accumulation may be undetectable in the early stages of 
MPAN [7]. Medial medullary lamina linear streaking on 
T2 sequences is an important sign supporting a differential 
diagnosis of MPAN [5]. Cerebral and cerebellar atrophy 
may be observed in the late stages [5]. Rare cases have been 
reported with a so-called ‘eye-of-the-tiger’ pattern in MRI, 
defined as hyperintensity in the anteromedial area of GP 
surrounded by low-signal intensity rings on a T2-weighted 
MRI [7, 8]. This MRI pattern is typical for pantothenate 
kinase-associated neurodegeneration (PKAN), which is the 
most common subtype of NBIA [1, 9].
The pathogenic variations in C19orf12 lead to MPAN 
through a possible defect affecting fatty acid biosynthesis and 
branched-chain amino acid metabolism [1, 10]. C19orf12 is 
also responsible for another allelic disease, namely hereditary 
spastic parapalegia (HSP) type 43 (MIM: 615043). HSP is ba-
sically an umbrella term for different rare neurodegenerative 
diseases that feature progressive spasticity of the lower limbs. 
Brain iron accumulation is not obvious in HSPs. Below, we 
present genetic findings of eight patients from seven Turkish 
families, along with their clinical and neuroimaging findings. 
We discuss the implications on the MPAN phenotype.
Patients and methods
Fourteen patients from 13 different families having pro-
gressive motor symptoms with irritative pyramidal signs and 
iron accumulation in basal ganglias were recruited in this study 
for a possible genetic diagnosis of MPAN (Supplementary 
Tab.1). All patients had previously tested negative for patho-
genic variations in PANK2 associated with PKAN. Informed 
consent was obtained from the patients and family members 
in accordance with the ethics approval obtained for the study 
from the Ethics Committee of Istanbul University, Istanbul 
Faculty of Medicine.
Genetic analysis
G enomic  DNA was  i s o l ate d  f rom p er iphera l 
blood using standard protocols. All exons and exon-in-
tron boundaries of the C19orf12 transcript variant 
NM_001031726.3 (ENST00000392278.2) coding the largest 
protein isoform were investigated for sequence variations 
using PCR and Sanger sequencing protocols. This reference 
transcript was also used to perform all variant annotations. 
Segregation analysis was performed in available family mem-
bers upon identification of a potentially causative variation. 
Primer sequences are given in the supplementary data. PCR 
conditions are available upon request. Sequence data was an-
alysed using a CLC Main Workbench v6.5. (CLC Bio, Aarhus, 
Denmark). The frequency of identified variations was evalu-
ated through the Genome Aggregation Database (GnomAD). 
All variants were annotated with an ENSEMBL-Variant Effect 
Predictor to identify all possible consequences on RNA and 
protein structure and also to evaluate with in silico tools, 
namely SIFT and Polyphen.
Results
We detected seven different potentially pathogenic 
C19orf12 variants in eight patients from seven families. A re-
view of the clinical and genetic findings of these patients is 
set out in Table 1. Two of these variants were associated with 
MPAN for the first time in this study, including c.194G > A in 
rs752450983 locus and one novel variant c.24G > C. These two 
variants were submitted to the freely accessible NCBI ClinVar 
Database, with SUB4966204 and SUB4967569 submission 
numbers respectively. All variants were in the homozygous 
state except for the variants of two siblings in Family 3, which 
were confirmed to be in a compound heterozygous state by 
segregation analysis. c.32C > T; p.(Thr11Met) (rs397514477), 
which has previously been reported to be common among 
adult Turkish patients with MPAN, was found to be homo-
zygous in two unrelated patients [4]. Figure 1 shows three 
selected variants for which segregation analysis was possible.
Interestingly, another patient (M8) was found to be 
heterozygous for a single variant in C19orf12 gene, which 
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has conflicting predictions of pathogenicity in ClinVar 
(rs146170087). Although the alternative allele frequency 
(AAF = 0.002) is relatively high compared to other variants 
identified in this study, it still fits the carrier frequency esti-
mation of MPAN (carrier frequency range of 0.002–0.005 for 
MPAN with a prevalence of 1–9:1,000,000 from Orphanet; 
ORPHA:289560). However, the variant was in a heterozygous 
state and another accompanying allele was not detected in any 
C19orf12 regions analysed.
The age of onset for patients with MPAN variants ranged 
from 9 to 27 years (Tab. 1). The most frequent clinical pre-
sentation was lower extremity-onset spasticity with dystonia 
(5/8). All patients had dystonia except for M5. The phenotype 
of patient M5 was submitted to the NCBI ClinVar Database 
with the SUB4967579 submission number. Among adult-onset 
MPAN patients, the initial symptoms can be listed as psychosis, 
dystonia-parkinsonism, and spasticity.
The brain MRIs of all patients were suggestive for iron 
accumulation equally at GP and SN. Five of them had hyper-
intense streaking of the medial medullary lamina, between 
the external and the internal part of the GP on T2 and FLAIR 
sequences. This radiological feature is not specific for a par-
ticular clinic. In patient M4, the medial streaking of GP was 
reminiscent of the ‘eye of the tiger’ sign common to PKAN 
(Fig. 2). Global brain atrophy was present in four patients, 
who also showed cognitive decline.
Optic atrophy, seizures and peripheral sensory-motor 
axonal neuropathy were the other clinical findings. Although 
optic atrophy was detected on examination in all patients, no 
patients had visual complaints. Patient M8 had a history of gen-
eralised seizures. Patient M6 had frontal intermittent rhythmic 
delta activity (FIRDA) in her EEG. Polyneuropathy was de-
tected in two siblings from Family 3 with C19orf12 compound 
heterozygous variations. Generalised dystonia was the most 
prevalent symptom for patients M3 and M8. These patients 
died aged 29 and 34, respectively, due to status dystonicus.
Discussion
Herein, we present genetic analyses and associated clinical 
findings for seven C19orf12 variants identified in a cohort of 
14 patients from 13 families with NBIA. Differential genetic 
diagnosis of MPAN was reached in seven patients from six 
families upon identification of biallelic C19orf12 variants. 
One patient had a monoallelic C19orf12 associated variant 
with inconsistent evaluations of pathogenicity (rs146170087). 
NBIA patients from the remaining six families with het-
erogeneous clinical findings were negative for potentially 
pathogenic C19orf12 variants, and were therefore noted as 
good candidates for exome sequencing for the identification 
of new genes for NBIA.
In our cohort with C19orf12 variants, the age of onset 
was dramatically clustered into two groups: MPAN started at 
ages 9 to 12, or 22 to 27. We wondered whether the variant 
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Figure 1. Segregation analysis in three families. (A) Patients M3 
and M4 from Family 3 are found to be compound heterozygotes for 
c.24G > C (novel) and c.204_214del variants. (B) Patient M2 from 
Family 2 is homozygous for c.199delG variant, while his healthy 
sisters do not carry this variant. (C) Patient M5 from Family 4 is 
homozygous for c.205G > A. Parents and one of his sisters are 
carriers for the variant
Figure 2. Brain MRI findings for Patient M4. Axial T2-weighted ima-
ge of M4 shows hypointensities at bilateral globus pallidi indicative 
of iron accumulation. Red arrows mark abnormal hyperintense 
signals in the middle of the globus pallidus, which is known as 
medial streaking. Medial streaking is so marked in this patient that 
it could be confused with the ‘eye of the tiger’ sign
type had any impact on this strict assemblage. At first glance, 
both missense and frameshifting variants are found in the 
early-onset group. However, re-annotation of the variants 
with VEP revealed a potential splicing effect for variants 
c.24G > C and c.194G > A, which alter the first nucleotide 
of exons 2 and 3, respectively. Interestingly, the missense 
variant c.205G > A (rs515726205) residing 12 bp into exon 
3 has the potential to alter splicing, as suggested by the 
Human Splice Finder algorithm. A potential frameshifting 
effect by a splicing impact may be associated with earlier 
disease onset. RNA-based analyses are required in large co-
horts with early-onset MPAN to test this effect on different 
C19orf12 transcripts. C19orf12 is a small gene with exons 
ranging from 2 to 4 in different. Therefore, it is not possible 
to predict if the frameshifting effect results in null alleles 
through the nonsense mediated decay (NMD) mechanism 
or truncated proteins.
The patients who carried variant c24G > C, i.e. M3 and 
M4, showed a catastrophic disease progression characterised 
by cognitive decline, spasticity, and dystonia. Patient M3 died 
aged 36 due to a respiratory infection. His sister, M4, has 
been bedridden since her late twenties. In a patient with c 
194G > A, M1, spasticity and dystonia were the prominent 
symptoms. Despite pharmacological treatment with baclofen, 
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trihexyphenidyl and intra-muscular botulinum toxin injec-
tions, she underwent deep brain stimulation surgery at the 
age of 18. There is no MPAN-specific treatment option. The 
therapeutic effect of iron chelation with deferiprone in NBIA 
has not been proven. Treatment of spasticity, dystonia, and 
parkinsonism, as well as significant neuropsychiatric symp-
toms, are indicated in MPAN [1, 4, 9].
In patients with NBIA, dystonia with spasticity, espe-
cially in the lower extremities, are frequent symptoms for 
childhood- and adolescence-onset MPAN. Dystonia and 
pyramidal symptoms are also prevalent motor symptoms 
common to both age groups. A late onset, but a rapidly 
progressive course with psychiatric symptoms and par-
kinsonism are features confined to adult-onset MPAN [4, 
6, 10]. The rapid progressive course includes both motor 
deterioration and cognitive decline, which eventually leads 
patients to be bed-bound. The c.32C > T; p.(Thr11Met) 
variant has previously been reported as the most frequent 
variant in Turkish adult-onset MPAN cases [4]. In our co-
hort, we found this variant in two of our three adult-onset 
MPAN cases. At this point, we would like to emphasise the 
possibility of the misinterpretation of clinical findings of 
late-onset MPAN patients. For example, patient M6 with 
homozygous c.32C > T; p.(Thr11Met) variant was first sent 
to a psychiatry clinic due to catatonic psychosis. Further 
neurological evaluations revealed Parkinson-like findings 
with predominant dystonia. Only then was she assigned 
for MRI analysis which led to the identification of iron 
accumulation in the brain. She then received dopaminergic 
therapy with a good response. Adult-onset MPAN should 
also be distinguished from atypical neuroaxonal dystrophy 
(NAD) due to PLA2G6 mutations [5]. Both MPAN and atyp-
ical NAD show dystonia-parkinsonism and iron deposition 
at GP and SN. Atypical NAD differs from MPAN in terms 
of cerebellar findings including cerebellar atrophy and eye 
movement anomalies [1, 11]. A correct genetic diagnosis 
will in turn assist in such differential diagnoses.
The third adult-onset MPAN case had an interesting 
genetic finding: we could only detect heterozygosity for 
a relatively common variant c.424A > G; p.(Lys142Glu) in 
C19orf12. This variant was originally reported to be patho-
genic and found to be in a compound heterozygous state with 
c.205G > A; p.(Gly69Arg) [1]. However, since this original 
report, this variant has had conflicting interpretations of 
pathogenicity ranging from benign to pathogenic in ClinVar. 
Because this patient had characteristic adult-onset MPAN 
findings with fast progression and death only two years after 
the emergence of initial symptoms, we cannot exclude the 
possibility that an as yet unidentified variant, maybe a CNV 
event along with c.424A > G; p.(Lys142Glu), was responsible 
for his condition.
Pathogenic variations in C19orf12 are responsible for 
two allelic diseases with autosomal recessive inheritance: 
MPAN and spastic paraplegia (SPG) type 43 [12]. SPGs or 
hereditary spastic paraplegias (HSPs) are a heterogenous 
group of rare neurological disorders characterised by pro-
gressive lower extremity spasticity without apparent brain 
iron accumulation. The condition is designated as compli-
cated HSP if spasticity is accompanied by additional features 
including cognitive impairment, cerebellar syndrome, 
thin corpus callosum, or neuropathy. In this sense, patient 
M5 with early-onset MPAN had a distinct and overlapping 
clinical course with complicated HSP. Our patient had slowly 
progressive spastic paraparesis without extrapyramidal 
signs. Distal muscle atrophy with weakness was present. 
He had knee flexion and Achilles tendon contractures. 
Nerve conduction study was normal at the age of 15, but he 
had first motor neuron signs at needle electromyography. 
He had mild mental retardation and optic atrophy. There 
was no evidence for dystonia, parkinsonism or any other 
extrapyramidal findings. Therefore, his clinical picture 
was compatible with complicated HSP, except for the iron 
accumulation in his brain MRI (Fig. 3). Therefore, patient 
M5, who is currently 22, has restricted the differential di-
agnosis of early-onset MPAN, as he has not yet developed 
either dystonia or parkinsonism.
Although MPAN demonstrates a wide phenotypical 
spectrum, the most common finding is iron accumulation 
equally in GP and SN and medial medullary lamina linear 
hyperintense streaking on T2 sequences. In some cases, 
such as patient M4 when the linear streaking is prominent, 
it resembles the ‘eye of the tiger’ sign (Fig. 2). This can lead 
to a misdiagnosis. In PKAN cases, the hyperintensity of GP 
is located in the anteromedial area of GP on a T2-weight-
ed MRI. Global brain atrophy and spasticity may help to 
distinguish MPAN from PKAN. As shown in our cohort, 
most MPAN cases had brain atrophy and all had spasticity. 
Brain atrophy and spasticity are not features of the PKAN 
phenotype [9].
The C19orf12 variants caused a wide spectrum of 
overlapping phenotypes and histopathological findings. 
MPAN can present as juvenile ALS [3], HSP [12], Behr 
syndrome [13] and dystonia-parkinsonism [1]. Lewy 
bodies, tangles, spheroids, and tau pathology are known 
in MPAN histopathology. Cognitive decline, global brain 
atrophy, parkinsonism, and histopathological findings show 
another overlap between MPAN and other Lewy body and 
taupathy-associated neurodegenerative diseases [1]. The 
clinical involvement in MPAN is not uniform. Variable 
degrees of cognitive decline, pyramidal and extrapyrami-
dal findings are seen in MPAN patients. The C19orf12 has 
been reported to code for a mitochondrial and endoplasmic 
reticulum membrane protein responsible for the transfer of 
essential lipids, and it has a role in calcium and magnesium 
metabolism and in autophagosome formation [12, 14]. New 
functional studies of C19orf12 will eventually shed light on 
the overlapping phenotypes such as HSP and Parkinson’s 
and Alzheimer’s diseases.
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Figure 3. Brain MRI findings for Patient M5. (A) The T2 and (B) T2_tse_dark fluid weighted axial section images showing hypointensity at 
globus pallidi. White arrows indicate confluent medial streaking in the globus pallidus (B)
A B
Conclusion
We present an MPAN series with a wide range of clinical 
and genetic findings. We have associated two pathogenic 
variants [c.24G > C; p.(Lys8Asn) and c.194G > A; p.(Gly65G-
lu)] with the MPAN phenotype for the first time. We have 
also supplied a genetic diagnosis of MPAN to a patient with 
atypical findings, who clinically resembled complicated HSP 
except for iron accumulation in his brain. The phenotypic 
presentation of this patient brought us to the conclusion 
that the clinical spectrum of MPAN may exclude dystonia 
and parkinsonism for at least some of the cases. The variant 
c.32C > T; p.(Thr11Met) common to Turkish adult-onset 
MPAN patients was also found to be predominant for ge-
netically defined late-onset MPAN patients in our cohort. 
Finally, we would like to highlight the possibility that frame-
shifting variants could be associated with early-onset MPAN.
Ethics: This study was approved by the Ethics Committee of 
Istanbul Faculty of Medicine, Istanbul University (protocol num-
ber 2015/12837/1.015.223). Written informed consents were 
received for/from patients authorizing us to use their medical 
data in this publication.
Acknowledgments: The authors wish to thank the patients 
and their families for participating in this study. This work 
was supported by grant from the Scientific Research Projects 
Coordination Unit of Istanbul University, Project Numbers 
TSA-2018-27512 and TDK-2017-26646.
References
1. Hartig MB, Iuso A, Haack T, et al. Absence of an orphan mitochondrial 
protein, c19orf12, causes a distinct clinical subtype of neurodegene-
ration with brain iron accumulation. Am J Hum Genet. 2011; 89(4): 
543–550, doi: 10.1016/j.ajhg.2011.09.007, indexed in Pubmed: 
21981780.
2. Schottmann G, Stenzel W, Lützkendorf S, et al. A novel frameshift 
mutation of C19ORF12 causes NBIA4 with cerebellar atrophy and 
manifests with severe peripheral motor axonal neuropathy. Clin Genet. 
2014; 85(3): 290–292, doi: 10.1111/cge.12137, indexed in Pubmed: 
23521069.
3. Deschauer M, Gaul C, Behrmann C, et al. C19orf12 mutations in 
neurodegeneration with brain iron accumulation mimicking juveni-
le amyotrophic lateral sclerosis. J Neurol. 2012; 259(11): 2434–
2439, doi: 10.1007/s00415-012-6521-7, indexed in Pubmed: 
22584950.
4. Olgiati S, Doğu O, Tufekcioglu Z, et al. The p.Thr11Met mutation 
in c19orf12 is frequent among adult Turkish patients with MPAN. 
Parkinsonism Relat Disord. 2017; 39: 64–70, doi: 10.1016/j.parkrel-
dis.2017.03.012, indexed in Pubmed: 28347615.
5. Hogarth P, Gregory A, Kruer MC, et al. New NBIA subtype: genetic, clini-
cal, pathologic, and radiographic features of MPAN. Neurology. 2013; 
80(3): 268–275, doi: 10.1212/WNL.0b013e31827e07be, indexed 
in Pubmed: 23269600.
6. Dogu O, Krebs CE, Kaleagasi H, et al. Rapid disease progression 
in adult-onset mitochondrial membrane protein-associated neuro-
degeneration. Clin Genet. 2013; 84(4): 350–355, doi: 10.1111/
cge.12079, indexed in Pubmed: 23278385.
7. Horvath R, Holinski-Feder E, Neeve VCM, et al. A new phenotype of 
brain iron accumulation with dystonia, optic atrophy, and periphe-
ral neuropathy. Mov Disord. 2012; 27(6): 789–793, doi: 10.1002/
mds.24980, indexed in Pubmed: 22508347.
8. Skowronska M, Kmiec T, Kurkowska-Jastrzębska I, et al. Eye of 
the tiger sign in a 23 year patient with mitochondrial membrane 
protein associated neurodegeneration. J Neurol Sci. 2015; 352(1-
2): 110–111, doi: 10.1016/j.jns.2015.03.019, indexed in Pubmed: 
25819119.
9. Akcakaya NH, Iseri SU, Bilir B, et al. Clinical and genetic features of 
PKAN patients in a tertiary centre in Turkey. Clin Neurol Neurosurg. 
483www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Nihan Hande Akçakaya et al., Clinical and genetic spectrum of an orphan disease MPAN
2017; 154: 34–42, doi: 10.1016/j.clineuro.2017.01.011, indexed in 
Pubmed: 28113101.
10. Tschentscher A, Dekomien G, Ross S, et al. Analysis of the 
C19orf12 and WDR45 genes in patients with neurodegenera-
tion with brain iron accumulation. J Neurol Sci. 2015; 349(1-2): 
105–109, doi: 10.1016/j.jns.2014.12.036, indexed in Pubmed: 
25592411.
11. Illingworth MA, Meyer E, Chong WK, et al. PLA2G6-associated neu-
rodegeneration (PLAN): further expansion of the clinical, radiologi-
cal and mutation spectrum associated with infantile and atypical 
childhood-onset disease. Mol Genet Metab. 2014; 112(2): 183–
189, doi: 10.1016/j.ymgme.2014.03.008, indexed in Pubmed: 
24745848.
12. Landouré G, Zhu PP, Lourenço CM, et al. NIH Intramural Sequencing 
Center. Hereditary spastic paraplegia type 43 (SPG43) is caused by 
mutation in C19orf12. Hum Mutat. 2013; 34(10): 1357–1360, doi: 
10.1002/humu.22378, indexed in Pubmed: 23857908.
13. Kleffner I, Wessling C, Gess B, et al. Behr syndrome with homozygous 
C19ORF12 mutation. J Neurol Sci. 2015; 357(1-2): 115–118, doi: 
10.1016/j.jns.2015.07.009, indexed in Pubmed: 26187298.
14. Venco P, Bonora M, Giorgi C, et al. Mutations of C19orf12, co-
ding for a transmembrane glycine zipper containing mitochondrial 
protein, cause mis-localization of the protein, inability to respond 
to oxidative stress and increased mitochondrial Ca²+. Front Ge-
net. 2015; 6: 185, doi: 10.3389/fgene.2015.00185, indexed in 
Pubmed: 26136767.
